Di Bacco, A., Bahlis, N. J., Munshi, N. C., Avet‐Loiseau, H., Masszi, T., Viterbo, L., . . . Moreau, P. (2020). c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma. European journal of haematology, 105(1), 35-46. https://doi.org/10.1111/ejh.13405
Citace podle Chicago (17th ed.)Di Bacco, Alessandra, et al. "C‐MYC Expression and Maturity Phenotypes Are Associated with Outcome Benefit from Addition of Ixazomib to Lenalidomide‐dexamethasone in Myeloma." European Journal of Haematology 105, no. 1 (2020): 35-46. https://doi.org/10.1111/ejh.13405.
Citace podle MLA (9th ed.)Di Bacco, Alessandra, et al. "C‐MYC Expression and Maturity Phenotypes Are Associated with Outcome Benefit from Addition of Ixazomib to Lenalidomide‐dexamethasone in Myeloma." European Journal of Haematology, vol. 105, no. 1, 2020, pp. 35-46, https://doi.org/10.1111/ejh.13405.